Immune Escape Articles & Analysis
7 news found
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. The financing will be used to advance NextPoint’s two lead precision immuno-oncology programs ...
ByBayer AG
Airfinity predicts a potential ‘twindemic’ of COVID-19 and flu could overwhelm hospitals this winter. The analysis focuses on two potential scenarios, based on data from previous winter COVID-19 waves driven by the Alpha and Omicron BA.1 variants as well as historical flu admissions from 2017-2018, the last bad flu season, as another bad flu season is expected this year based on ...
CD ComputaBio, a reliable computational biology service provider located in New York, is always hammering away at research and trials in order to provide customers with access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. The company recently announced the launch of PD-L1 targeting service for cancer research. Over the past decade, ...
GAITHERSBURG, Md., March 17, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) and Zephyr AI (Zephyr) today announced a strategic partnership focusing on the discovery and validation of novel targets for new T-cell-mediated therapies in oncology. Combining Zephyr’s proprietary artificial intelligence (AI) and algorithmic technology with NexImmune’s Artificial Immune Modulation ...
Despite the slow evolutionary rate of SARS-CoV-2 relative to other RNA viruses, its massive and rapid transmission during the COVID-19 pandemic has enabled it to acquire significant genetic diversity since it first entered the human population. This led to the emergence of numerous variants, some of them recently being labeled “variants of concern” (VOC), due to their potential impact ...
Company’s technologies and drug-hunting expertise now responsible for world’s first and second AI-designed drugs to enter Phase I testing Exscientia, a leading artificial intelligence (AI) driven pharmatech company, today announced the first AI-designed molecule for immuno-oncology to enter human clinical trials. The A2a receptor antagonist, which is in development for adult patients ...
iXensor, the pioneer of mobile health, today announced its “PixoTest® COVID -19 Antigen Self-Test Kit” has been granted by Taiwan FDA for EUA, in response to the recent peak of the epidemic and the new quarantine mandate of 0+7 taking effect on Oct 13th, Taiwan will officially enter the era of “self-initiated epidemic prevention”. The latest study of variant ...
ByiXensor